TNFR2 expression predicts the responses to immune checkpoint inhibitor treatments

Immune checkpoint inhibitors (ICIs) by targeting PD-1/PD-L1 or CTLA-4 have markedly improved the outcome of cancer patients. However, most solid tumor patients can’t benefit from such therapy. Identification of novel biomarkers to predict the responses of ICIs is crucial to enhance their therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Ping, Jiang, Mengmeng, Islam, Md Sahidul, Wang, Yiru, Chen, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971721/
https://www.ncbi.nlm.nih.gov/pubmed/36865537
http://dx.doi.org/10.3389/fimmu.2023.1097090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971721/
https://www.ncbi.nlm.nih.gov/pubmed/36865537
http://dx.doi.org/10.3389/fimmu.2023.1097090

Ejemplares similares